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Abstract 
 Multiple sclerosis is an immune-mediated disorder that affects the functioning of 
the central nervous system of 2—2.5 million people worldwide. This disease is 
characterized by the demyelination and damage of nerve cells, which causes physical 
disability. Multiple sclerosis causes scarring (sclera) of the neurons and leads to misfiring 
of the neural cells. The sclera causes the general symptoms of MS, which include fatigue, 
incontinence, and muscle weakness or lack of muscle control (“National Multiple 
sclerosis Society,” 2013). Multiple sclerosis currently does not have a cure, but there are 
some disease-modifying medications that have been used to mitigate the daily symptoms 
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 Multiple sclerosis is a disease that impairs neurological function through 
demyelination of white matter axons in the central nervous system. This review will 
address the common clinical features of the disease, symptomology, pathophysiology, 
and disease diagnosis and treatment methods. It includes a discussion regarding the 
epidemiology of the disease amongst different racial groups, as well as the geographic 
clusters and environmental factors that could play a part in disease prevalence. This 
review highlights genetic factors as well as autoimmunity and how they relate to MS 
disease progression. The body of review mentions current research in MS and discusses 
the future of MS treatments. 
Clinical Features 
 Multiple sclerosis is a unique disease because nearly any neurological symptom 
can be a symptom of MS. Multiple sclerosis is debilitating because it affects mostly 
autonomic nervous system function, so patients cannot consciously relieve their own 
symptoms. Common symptoms of multiple sclerosis include episodes of sensory 
dysfunction, including: impaired vision, loss of sensitivity, loss of motor control or 
paralysis, muscle spasms, ataxia, and L’hermitte’s sign (electrical tingling down the 
back) (“National Multiple sclerosis Society,” 2013). Hearing loss is less common. It can 
cause dizziness and vertigo, fatigue, and can have negative effects on sexual function. 
MS can also affect mood, which is regulated by neurotransmitter release in the brain, as 
well as damage the neurons that control moods, causing depression in MS patients 
(Bakshi et al., 2000).  
2 
Multiple sclerosis can be categorized into four general types, characterized by the 
severity, progression, and length of the episode. The four types of multiple sclerosis are: 
relapsing remitting, secondary progressive, primary progressive, and progressive 
relapsing. The reasons behind the different presentations of this disease are unknown, but 
research suggests that the types and relative numbers of immune cells in a particular case 
can affect the type and severity of multiple sclerosis (Gandhi, Laroni, & Weiner, 2010).  
 80% of patients have relapsing remitting MS. These patients have unpredictable 
episodes that include one or many of the symptoms described above, which disappear for 
a length of time, then return. These patients usually do not show long-term effects from 
these episodes. Secondary progressive MS occurs in 65% of people that began with 
relapsing remitting MS, and is characterized by a decrease in remissions over time. The 
remissions earlier in their disease become shorter and eventually do not remit.  People 
with secondary progressive MS experience persisting neurological effects from the 
damage. Primary progressive MS affects 10-15% of MS patients, and is different from 
other forms of MS because it is a slowly worsening progression with no remission after 
initial MS attacks. The disease and the neurological damage gradually worsen with no 
flare-ups. Progressive relapsing is the worst and least common form of MS, with 5% of 
people presenting with this type of MS. Progressive relapsing MS patients have 
immediate worsening of symptoms from their first MS attack, and do not have any 
remission. Relapses occur where old symptoms will return with greater severity, and the 
neurological damage will continue steadily (“National Multiple sclerosis Society,” 2013). 
Pathophysiology/pathogenesis 
 Multiple sclerosis is characterized by scarring of the neural cell axons, called sclera. 
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This sclera can be found in the white matter of the central nervous system, and the 
progression of MS has shown to decrease white matter in the brain by causing the 
demyelination of the axons (D’Aversa et al., 2013). The oligodendrocytes of the CNS 
create the myelin sheath, and it is unclear as to whether the oligodendrocytes are 
damaged or just do not function properly in MS patients (Smith & McDonald, 1999).  
Eventually, the neural cell will die from the lack of oligodendrocyte maintenance. 
Physiologically, the function of the myelin is to propagate the electrical signal along the 
axon from white matter to gray matter for signal processing, but the damage from MS 
causes the message to be misinterpreted through cross talk, which is a misdirected 
electrical signal, or the bare spots and scarring of the axon tissue inhibits the propagation 
of the signal altogether (Smith & McDonald, 1999). 
 It has been suggested that multiple sclerosis is caused by either genetic factors or by 
autoimmune response. The risk of developing MS is higher in people that have an 
immediate family member that has the disease, and the incidence is increased to 3% if a 
sibling has the disease and even up to 25% if a twin has MS (Korn, 2008).  The alleles 
IL2Rα, IL7R and CD58 genes expressed on leukocytes show increased likelihood of an 
autoimmune response (Korn, 2008).  
 MS is currently deemed an “immune-mediated disorder,” which essentially means 
that MS has the characteristics of an autoimmune disorder, but differs slightly. 
Autoimmunity results from cytotoxic CD4+ T cells interacting with self-antigens. 
However, the self-antigen that causes the autoimmune reaction in MS has not been 
elucidated, so MS cannot be considered autoimmune (“National Multiple sclerosis 
Society,” 2013). MS has the characteristics of autoimmunity because it results in an 
4 
inflammatory response that causes damage in the CNS. Self-antigen specific cytotoxic T 
cells enter the blood brain barrier and begin interacting with MHC class II molecules, 
where final differentiation of the T cells occurs and the CD4+ T cells fully mature. This 
causes the release of pro-inflammatory cytokines and chemokines (Korn, 2008). The 
cytokines IL-17 and IL-23 are found in higher percentages in MS lesions than in other 
autoimmune disorders, and are produced by Th17 cells. These cytokines and chemokines 
from the Th17 cells attract neutrophils, which undergo diapedesis to cross the blood brain 
barrier and begin attacking the myelin cells (D’Aversa et al., 2013). This progression of 
immune responses is the main cause for the demyelination and scarring of the CNS 
experienced by MS patients. 
Symptoms 
 The symptoms and frequency of the symptoms is one of the preliminary indicators 
that a person has multiple sclerosis. One of the main issues with diagnosing MS is that 
nearly any neurological abnormality can be a symptom of MS. The common symptoms 
of MS are usually associated with the autonomic nervous system, which makes living 
with the disease very difficult because the autonomic nervous system controls 
involuntary action(“National Multiple sclerosis Society,” 2013).  
 The common primary symptoms of MS include: full body fatigue, loss of motor 
control, temporary paralysis, ataxia, and dizziness and vertigo. Not only does it affect 
basic muscle control, it also causes incontinence, sexual dysfunction, and a tingling 
sensation down the back(“National Multiple sclerosis Society,” 2013). MS also affects 
sensory nerves, with vision loss or blurriness being the most common symptom. Hearing 
loss and loss of sensitivity, along with seizures and respiratory problems are much less 
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common (Bakshi et al., 2000).  
 Secondary symptoms can also result from the primary symptoms. Urinary tract 
infections are more common and are due to incontinence. The loss of motor control leads 
to inactivity, which leads to metabolism issues, loss of bone density, and loss of muscle 
tone. Tertiary symptoms are “the trickle down effects of the disease on [one’s] 
life,”(“National Multiple sclerosis Society,” 2013). Tertiary symptoms can be 
psychological, emotional, or social consequences of the disease, like not being able to 
drive cars, go to work, socialize, or maintain healthy relationships. Sometimes the 
emotional affects of MS can be cause for depression (Bakshi et al., 2000). 
 The severity and frequency of these symptoms, as well as the degree of lasting 
neurological damage, determines if someone has MS and what type of MS they have. 
Over the course of the disease, some symptoms may get worse, some may get better, and 
others may never disappear, which makes diagnosing and treating the symptoms of MS 
difficult (Korn, 2008; “National Multiple sclerosis Society,” 2013).  
Epidemiology 
 MS research gains its urgency because the disease affects 2-2.5 million people 
globally(“National Multiple sclerosis Society,” 2013). MS is also more common in 
Caucasians, predominantly of Northern European descent, than in Blacks, Asians, or 
Hispanics (“Rocky Mountain MS Center,” 2013). MS is extremely rare in certain 
populations, such as “the Australian Aboriginies, New Zealand Maoris, Inuit, Hungarian 
Romani, and Norwegian Lapps,” (“National Multiple sclerosis Society,” 2013). Multiple 
sclerosis is also twice as common in women as men. Current theory states this might be 
due to the constant hormonal changes that occur with females(Anthony et al., 2013). 
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 Multiple sclerosis is diagnosed usually in people between the ages of 20 and 50 
years old. MS is not usually diagnosed earlier than 20 years old because it is a 
progressive disease that is not identified until a patient has experienced multiple similar 
episodes that exhibit characteristics of MS. People may go months to years in between 
episodes, so diagnosis is a slow process(“National Multiple sclerosis Society,” 2013).  
Genetics 
 Multiple sclerosis is not considered a genetic disease, but there is an obvious 
positive correlation between parents or siblings that have MS and an increased likelihood 
of having the disease later in life. The global population has a 1 in 750 chance of getting 
MS, but people with an immediate family member affected have a 1 in 40 chance of 
getting MS. Identical twins have a 1 in 4 chance of getting MS if one of the twin has the 
disease (“National Multiple sclerosis Society,” 2013).This indicates that genetics is not 
the only factor in MS, because identical twins have the same genome, so if MS was a 
purely genetic disorder, both twins would have the disease. This shows that MS is also 
affected by environmental factors, or possibly pathogen induced (Anthony et al., 2013).  
 There has also been evidence that differences in the human leukocyte antigen 
(HLA) gene, located on chromosome 6, can have an increased chance of having MS. The 
human leukocyte antigen codes for the MHC class II molecule expressed by antigen 
presenting cells. Mutations of the HLA gene have shown a 20-60% increased 
predisposition to have an autoimmune disorder (Baranzini, 2012).  
Environmental Factors 
 The most common environmental factor that probably affects the incidence and 
prevalence of MS is the latitude where people live. MS is much less prevalent at 
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equatorial latitudes, and is much more common in people living above 40° latitudes. This 
could be because of less vitamin D synthesis in the body at higher latitudes. Research 
shows “vitamin D had a significant effect on the activity of 229 genes including IRF8, 
previously associated with MS,” but this theory has not been confirmed (Ramagopalan et 
al., 2010).  
 Infectious agents pose a theoretical cause for MS. The Epstein-Barr virus, as well 
as chlamydia pneumonia, HIV, and rabies have been proposed as infections that could 
trigger the self-reactive immune response.  Additionally, viruses, such as the herpes virus, 
can cause the animal model disease for MS, experimental autoimmune encephalomyelitis 
(EAE) (“National Multiple sclerosis Society,” 2013). The hygiene hypothesis states that 
people exposed to a large number of pathogens early in life prevents the disease 
development because the immune system can react to a more diverse antigen repertoire 
(Anthony et al., 2013). 
 Research also indicates that environmental factors such as pollution and toxic 
materials could be a trigger for MS. It has been theorized that the binding of 
environmental exogenous ligands to the aryl hydrocarbon receptor (AHR) found in MS 
lesions influences the progression of MS. MS patients show higher expression of the 
AHR in MS lesions, and the AHR is currently under review in the role it plays in MS 
presentation(Veldhoen & Duarte, 2010). The aryl hydrocarbon receptor binds many 
exogenous ligands, and is key in metabolizing xenobiotics and toxins (Hankinson, 1995). 
It is possible that the binding of environmental toxins to the AHR increases its activity 
and induces the proliferation of Th17 cells in MS patients(Stockinger, Veldhoen, & 
Hirota, 2009).  
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Diagnosis 
 Diagnosing multiple sclerosis is difficult for many reasons. Part of the issue is that 
multiple sclerosis presents in many different forms in each individual patient depending 
on what kind of MS they have and what symptoms are most prevalent. The initial 
indicator for MS is a record of the patient’s health history, with specific instances of an 
MS-type attack and either relapses between the symptoms or progressive worsening of 
their condition (Anthony et al., 2013). To be considered an MS attack, the symptoms 
must lasts for at least 24 hours and must be separated by at least 30 days (“National 
Multiple sclerosis Society,” 2013). 
 The main criteria for diagnosing MS include the following: 1. Locating at least two 
separate areas of damaged CNS tissue, 2. Ensuring that the damage occurred at least one 
month apart, and 3. Confirming it cannot be another neurological disease. These can be 
verified by taking patient history, performing a neurological exam and by using new 
imaging and lab techniques(“National Multiple sclerosis Society,” 2013). Magnetic 
Resonance Imaging (MRI), visual evoked potential (VEP), blood tests, and cerebrospinal 
fluid analysis, which tests for IgG bands (a possible source for axonal conduction 
blocking) in electrophoresis gels of CS fluid are some of the ways that the differential 
diagnosis of MS can be confirmed (“National Multiple sclerosis Society,” 2013; Rose 
M.D., Houtchens MSII, & Lynch M.D., n.d.). 
Treatment 
 There is no known cure or treatment for multiple sclerosis, because the direct cause 
for MS is still unclear. One of the techniques used to mitigate the symptoms of MS is 
administration of anti-inflammatory medications and corticosteroids, since most of the 
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damage is caused by inflammation. Corticosteroids are usually given as an immediate 
relief from a MS attack. However, steroids are not a good long-term treatment 
option(“National Multiple sclerosis Society,” 2013).  
 There are a few disease-modifying treatments that are used to decrease the number 
or severity of attacks, but these medications, like all medications, have their adverse side 
effects. There are medications such as Avonex, Betaseron, Extavia, and Rebif, which all 
mimic interferon beta- 1a or 1b, which is a common immunological messenger that helps 
balance pro-inflammatory and anti-inflammatory messengers within the brain (1,8). 
Some side effects of these injection-administered medications are rashes and bruising at 
the injection site, as well as flu like symptoms within 24 hours of injection (“National 
Multiple sclerosis Society,” 2013). 
 Other medications include Tecfidera (dimethyl fumarate), Aubagio (teriflunomide), 
Copaxone (glatiramer acetate), Novatrone (mitoxantrone), and Tysabri (natalizumab) 
(“National Multiple sclerosis Society,” 2013). These medications work by inhibiting 
immune cells, reducing inflammation, and preventing immune cells from crossing the 
blood brain barrier into the CNS (D’Aversa et al., 2013).  
Body of Review 
  The future direction of research involves understanding the biological and 
immunological processes behind the autoimmune inflammatory response seen in MS. 
Current research is investigating how the aryl hydrocarbon receptor (AHR) plays a role in 
T cell differentiation. The AHR can bind many ligands, and depending on the ligand and 
interleukins present, can initiate Th17 cell differentiation (Quintana, 2013). The 
mechanism for AHR binding is currently under review. There have been controversies 
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amongst researchers; a study by Quintana in 2013 (16) noted increased proliferation of 
Th17 cells and downregulation of Thelper cells, while Veldhoen (Veldhoen & Duarte, 
2010) found the opposite result. Understanding how exogenous ligands affect this 
receptor may lend insight as to what external factors could cause the disease. The AHR is 
also a good potential site for medical treatments because it can interact with many ligands 
(Quintana, 2013).  
 Another area of research is looking at the regulation of communication between 
antigen presenting cells and T cells through the RORγt transcription factor. The 
combination of interleukin-6 and transcription growth factor-beta (TGF-β) is imperative 
for the activation of RORγt, which induces the differentiation of a naïve T cell into a 
Th17 cell (Ivanov et al., 2006). Research suggests Th17 cells are one of the most 
destructive T cells in MS attacks (Zhou et al., 2007). Regulation of this transcription 
factor would inhibit the production of these Th17 cells, thereby reducing the 
inflammation in MS lesions.  
Conclusions 
 Multiple sclerosis is an immune mediated disorder that is characterized by 
inflammation and damage to the central nervous system (CNS). Inflammatory responses 
initiated by adaptive immune responses of CD4+ T cells targets self-antigens on 
myelinating cells within the brain and spinal cord (D’Aversa et al., 2013). This 
inflammatory reaction causes chronic demyelination of nerve cells, thereby impairing 
nervous signal transmission through the body(Anthony et al., 2013). There is also some 
evidence that people can be genetically predisposed to MS; people with an immediate 
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family member that has MS increases their likelihood ten fold to have the disease later in 
life (1,10).  
 Today, multiple sclerosis affects 2-2.5 million people globally, and is usually 
diagnosed in people 20-50 years old. Multiple sclerosis is twice as common in women as 
in men. MS affects most body processes, with the most common symptoms including 
overall fatigue, incontinence, muscle weakness, and loss of coordination. The exposed 
axons and scar tissue (sclera) formed by the healing process after an episode causes 
“cross talk” between neurons, and this cross talk causes the physical symptoms 
associated with MS (“National Multiple sclerosis Society,” 2013). 
There are various forms of multiple sclerosis characterized by the severity, 
progression, and length of the episode. The four types of multiple sclerosis are: relapsing 
remitting, secondary progressive, primary progressive, and progressive relapsing. The 
reasons behind the different presentations of this disease are unknown, but research 
suggests that the types and relative numbers of immune cells in a particular case can 
affect the type and severity of multiple sclerosis(1,8).  
 There is no cure for MS at this time, but there are many FDA approved medications 
that help mitigate the symptoms of MS(“National Multiple sclerosis Society,” 2013). 
Many of them mimic interferon-beta to help regulate levels and expression of pro-
inflammatory and anti-inflammatory cytokines(Korn, 2008). Current research is 
investigating the affect of regulating the aryl hydrocarbon receptor or the transcription 
RORγt, which have a role in T cell differentiation(Ivanov et al., 2006; Quintana, 2013; 
Zhou et al., 2007).   
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Chapter 2—The mechanism of T17 cell differentiation via expression of RORγt 
transcription factor through IL-6, IL-21 and IL-23 cytokine pathway 
Abstract  
 Autoimmune diseases and immune mediated disorders such as Multiple sclerosis 
and murine experimental autoimmune encephalomyelitis (EAE) are diseases caused by 
an immune response triggered against self-cell antigens. Activation of the RORγt 
transcription factor induces the differentiation of naïve T cells into Th17 cells when 
coupled with IL-6 and TGFβ. The resulting Th17 cells produce IL-17 which attract 
neutrophils to the CNS, where they cross the blood brain barrier and attack the myelin 
cells. Results showed that IL-6 and TGFβ are necessary to begin differentiation of naïve 
T cells into Th17 cells. IL-6 and TGFβ induce expression of IL-21 and IL-23, which 
promote differentiation by inducing RORγt and STAT3 transcription factors. IL-21 and 
IL-23 facilitate the translocation of RORγt into the nucleus where it transcribes the DNA 
necessary to differentiate and proliferate the Th17 cell. IL-23 is the terminal differentiator 
and RORγt is the limiting factor for differentiation of Th17 cells. Inhibition or regulation 










 Multiple sclerosis (MS) is an autoimmune disorder that damages myelinating cells 
in central nervous system (CNS) tissues. CD4+ T cells specific for self-antigens 
presented on these myelin cells cross the blood brain barrier and attack these cells, 
releasing cytokines and chemokines in the surrounding tissues. The most prevalent T 
cells found in MS lesions are Th17 cells, which are a specific subset of T cells that 
release IL-17, a powerful chemo-attractant of neutrophils (El-behi, Rostami, & Ciric, 
2010). These pro-inflammatory cytokines along with the attacking neutrophils causes an 
inflammatory response, which damages the neurons within the brain and spinal cord. This 
damage can be irreversible, causing life-long neuropathy (Science & In, 2006). 
 The differentiation and proliferation of Th17 cells, a new subset of CD4+ T cells, 
depends on other chemokines and cytokines within the surrounding tissue. Th17 
differentiation depends on the presence of IL-6 and TGFβ in order to transform a naïve T 
cell into a Th17 cell (Yang, Pappu, et al., 2008; Zhou et al., 2007). The IL-6 and TGFβ 
interact with the transcription factor RORγt, which activates specific genes within the cell 
DNA to induce differentiation (Sundrud & Rao, 2008). Murine models that have 
experimental autoimmune encephalomyelitis (EAE), the mouse-version of MS, show 
similar levels of Th17 cells within their CNS damage. Genetically altered CD4+ T cells 
deficient in RORγt do not differentiate into Th17 cells in the presence of IL-6 and TGFβ 
(Aranami & Yamamura, 2008). 
 Control of this pathway offers a possible treatment option for people suffering 
from MS attacks. By downregulating the RORγt receptor, Th17 cell differentiation is  
inhibited (Ivanov et al., 2006; Zhou et al., 2007). Because Th17 cells are the cause for 
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most of the inflammatory damage within MS patients, decreasing the number of these 
cells within an MS lesion would prevent inflammatory damage, thus reducing the 
severity of MS.  
Mechanism 
 The differentiation of Th17 cells occurs by a multistep process involving 
receptors and various signaling and interleukin molecules. The basic mechanism for this 
differentiation occurs when tumor growth factor-beta (TGFβ) and interleukin-6 (IL-6) 
bind and interact with the RORγt receptor, which is the limiting step in the pathway, on 
naïve T cells.  
The RORγt receptor is an orphan nuclear receptor, which is similar in structure 
and function to nuclear receptors, however the endogenous ligand that binds to the 
receptor is not clearly understood; therefore, the term “orphan” is added to indicate 
ambiguity(Ivanov et al., 2006). Nuclear receptors have the ability to translocate into the 
cell and bind to DNA to regulate the expression of certain genes, making them a 
transcription factor (Sundrud & Rao, 2008). The RORγt then activates the genes 
necessary to transform the naïve T cell into a Th17 cell. Without RORγt, differentiation 
of Th17 cells and IL-17 production does not occur. 
This mechanism is regulated by the cytokine milieu within the lesion. Various 
positive and negative feedback loops are necessary to direct the differentiation of a naïve 
T cell into the Th17 cell. Naïve T cells express a functional IL-6 receptor composed of 
IL-6Rα and signaling subunit gp130 (Korn, Bettelli, Oukka, & Kuchroo, 2009). The 
presence of TGFβ increases the expression of IL-6Rα, and is also required to maintain the 
responsiveness to IL-6 during differentiation. Ligand binding to the heterodimeric 
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receptor consisting of signaling subunit gp130 and WZX-1 leads to the activation of 
transcription factor STAT3, which is needed to induce RORγt expression (Korn et al., 
2009).  
STAT3 and interleukin-21 (IL-21) are amplifiers of IL-17 production in 
differentiated Th17 cells. STAT3 is located within the cytosol and translocates into the 
nucleus, and phosphorylation of STAT3 along with its binding to the Il17 and Il21 
promoters within the nucleus is required for constant IL-17 production in Th17 cells. IL-
21 production is induced by the presence of IL-6 and binding of STAT3. IL-21 functions 
in a positive feedback autocrine loop along with IL-23 and TGFβ to induce IL-17 





 Elucidation of this mechanism was determined using murine models infected with 
EAE, which is the rodent version of MS. These mice were genetically modified to have T 
cells deficient in certain receptors and genes necessary for this pathway. By looking at 
various levels of cell, receptor, and cytokine expression, the various components and 
intermediates in the pathway were identified.  
Production of naïve T cells for experimentation  
In order to prove the presence of IL-17 expression from Th17 cells in reporter 
mice, a Th17 reporter mouse modified to express red fluorescent protein (RFP) in the IL-
17 and IL-17F gene sequence was used (Lee et al., 2009). The reporter mice and wild 
type mice were injected with EAE. Once the mice reached a clinical score of 3 
(characterized by hind leg paralysis), CNS fluid was extracted and analyzed (Lee et al., 
2009). The reporter mice showed 20% of CD4T cells expressing RFP (figure 3E). Then 
real-time PCR (RT-PCR) was performed to determine the other types of mRNA 
expressed in the EAE lesions. RT-PCR showed expression of IL-17A, IL-17F, IL-22, and 
IL-23R mRNA expression (figure 1F) (Lee et al., 2009). There were low levels of 
expression of IFNgamma and T-bet, which are characteristically upregulated in 
regulatory T cells. This is indicative of the inverse relationship between differentiation of 
Treg cells and Th17 cells (Yang, Nurieva, et al., 2008).  The presence of IL-17A, IL-17F, 
IL-22, and IL-23R mRNA expression proved the reporter mice were acceptable for 
further experimentation.
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TGFβ effects on Th17 differentiation 
Research suggests that there is a reciprocal relationship between Treg cells, which 
are anti-inflammatory, and Th17 cells, which are pro-inflammatory (Yang, Nurieva, et 
al., 2008). The differentiation depends on the presence of IL-6; naïve T cells differentiate 
into Treg cells in the presence of TGFβ, and differentiate into Th17 cells in the presence 
of IL-6 and TGFβ. Xuexian et al. tested this theory by using undifferentiated T cells from 
C57BL/6 mice, and treating them with an inhibitor of TGFβ RI kinase at various stages 
of development (Figure 4A) (Yang, Nurieva, et al., 2008). The addition of SB431542 (the 
TGFβ RI kinase inhibitor) at days 0-1 resulted in over an 80% reduction of IL-17 
production when compared to the wild type, as well as decreased expression of IL-17F, 
RORα, RORγt, and IL-23R mRNA. There was a 50% reduction in IL-17 production 
when the inhibitor was added on day 2, and approximately a 20% reduction of IL-17 
production when added on day 3 (Figure 4A) (Yang, Nurieva, et al., 2008).  
Figure 3 E,F: Levels of mRNA expression in CD4+T cells genetically modified to express RFP.  
(E) IL-17F-RFP expression in CD4+ T cells. EAE was induced in Il17f rfp and WT mice and 
infiltrates from the CNS of the EAE mice were isolated at the clinic score 3. FACS in a CD4+ gate 
was used to analyze IL-17F-RFP expression. (F) RFP+ and RFP- CD4+ cells were sorted from CNS 
of Il17f rfp EAE mice, and then was analyzed by real-time RT-PCR. Data were normalized to a 





TGFβ receptor activates Smad4 
Smad proteins are intracellular proteins that transmit extracellular signals to the 
nucleus, where they induce gene transcription. Activation of the TGFβ type II receptor—
a transmembrane protein with a cytoplasmic serine/threonine kinase domain—induces 
the activation of transcription factors Smad2 and Smad3 proteins, which are then 
phosphorylated and bind to Smad4 which translocates into the nucleus (Lee et al., 2009; 
Wrana et al., 1992). In order to understand the importance of Smad4 in T cell 
differentiation, mice deficient for Smad4 in their T cells were bred, and the relative 
number and types of T cells within the EAE lesions were analyzed using flow cytometry 
and RT-PCR. Mice deficient in Smad4 showed normal numbers of CD4+ T cells, CD8+ 
T cells, and Treg cells (Figure 5 E, F). Therefore, Smad4 is not necessary for T cell 
development, because the cells deficient in Smad4 still produced normal numbers of T 
cells (Lee et al., 2009; Yang, Nurieva, et al., 2008). 
Smad4 deficient T cells were then stimulated under the Th17 cell differentiation-
inducing environment containing IL-6 and TGFβ to test how Smad4 influenced Th17 cell 
Figure	  4A.	  TGFβ effects on generation of Th17 cells. Naive T cells were 
activated under Th17 (TGF-b, IL-6, IL-23, anti-IFN-g, and anti-IL-4) conditions, 
or a TGF- bRI kinase inhibitor (SB431542, 5 mM) was added at different time 
points as indicated. Cells were assessed for IL-17 and IFN-g production and 
Foxp3 expression after 4 days of stimulation by intracellular staining. (A) A 
representative dot-plot graph is shown in the left panel, and the numbers in 
quadrants represent the percentages. In the right panel, the percentage of (A) IL-
17+ cells for six independent experiments is indicated. (Yang, Nurieva, et al., 
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function. Results showed reduced expression of Foxp3 receptors on Smad4 deficient T 
cells when compared to WT (figure 5E), but both showed similar production of IL-17 
(figure 5F) (Yang, Nurieva, et al., 2008). From these results it can be concluded that 
Smad4 is necessary for the expression of Foxp3 receptors but not for the production of 
IL-17 in Th17 cells.  
 
Figure 5 E,F. Flow cytometry of IL-17 levels in response to Foxp3 and to Smad4 
deficient cells. “Naive Smad4-sufficient or -deficient T cells were activated under (E) 
iTreg or (F) Th17 cell conditions, and IL-17, IFN-g, and Foxp3 expression was analyzed 
by intracellular staining. Numbers in quadrants represent the percentages,” (Yang, 
Nurieva, et al., 2008).  
 
Role of IL-6 in T cell differentiation 
Mice deficient in IL-6 show average levels of T cells, but a significantly reduced 
number of autoimmune diseases such as EAE (Zhou et al., 2007). Measuring levels of IL-
17 produced in mice deficient in IL-6 helped determine the role of IL-6 in T cell 
differentiation. These IL-6 deficient mice showed a ten fold reduction in the amount of 
IL-17 produced (Figure 6A)(Ivanov et al., 2006). RT- PCR performed with mRNA from 
TCRb+CD4+ cells showed similar reductions in IL-17 production in the mutant mice 
versus the WT. Additionally, IL-6 deficient mice did not express RORγt or IL-23R (the 
inducer of IL-23) (Figure 6B)(Ivanov et al., 2006). Another study performed by Zhou et 
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al. showed that IL-6 is a strong upregulator of the IL-21 gene, which was confirmed 
using RT- PCR for IL-21 mRNA. This study also confirmed the results by Ivanov et al., 
showing that mice deficient in IL-6 have lower levels of RORγt, IL-17, IL-17F and IL-
23R. IL-6 is necessary for induction of transcription factors such as RORγt and 
interleukins responsible for IL-17 production (Zhou et al., 2007). IL-6 is the initial 
differentiator of naïve T cells to continue to the Th17 cell lineage. IL-6 when coupled 
with TGFβ leads to Th17 cell differentiation, whereas just TGFβ leads to Treg cell 
differentiation. 
Figure 6 A. Flow cytometry of IL-17 expression in IL-6 deficient mice. Lamina 
propria cells were taken from 17 week old mice and were analyzed using 
PMA/lonomycin in Brefeldin A.  
Figure 6 B. Levels of RORγt, IL-23R, IL-17 and IL-17F mRNA expression in RT-
PCR of IL-6 deficient mice. Error bars in B were determined using the standard 
deviation method. (Ivanov et al., 2006) 
 
Role of IL-21 and IL-23 on RORγt expression 
To test the importance of IL-21 and Il-23 on RORγt expression, Zhou et al. 
transduced RORγt deficient CD4+T cells with IL-23R retrovirus, which is needed to 
create a functional IL-23 receptor. IL-17 was produced in the cells differentiated with the 
cytokines TGFβ and IL-23, but only in the cells with the IR-23R retrovirus encoded in 
the genome. IL-23 alone induced some production of IL-17, but was not as successful as 
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when TGFβ was included (Zhou et al., 2007). IL-21 also worked together with TGFβ to 
induce higher levels of IL-17. It was also determined that IL-21 is a downstream 
regulator of Th17 cell differentiation, because when IL-6 deficient cells were 
differentiated with TGFβ and IL-21, levels of IL-17 were mostly unchanged (Figure 7b) 
(Zhou et al., 2007).  
Zhou et al. then tested the role of RORγt in response differentiation by IL-21 or 
IL-23. RORγt deficient cells were transduced with IL-23R and stimulated in the presence 
of TGFβ and IL-23. These cells produced little to no IL-17. The same results were found 
when the RORγt deficient T cells were transduced with IL-21R. (Figure 7 B). RORγt was 
upregulated in response to IL-21 and IL-23 in naïve T cells. The levels of RORγt 
expression were even higher when the cells were stimulated with IL-21, 23 and TGFβ 
(Figure 7 C) (Zhou et al., 2007). Therefore, IL-21 and IL-23 can replace IL-6 in certain 
lines of Th17 cell differentiation, and is used to promote expression of RORγt in 
differentiating T cells. 
 
Figure 7 B: Flow cytometry of the expression of IL-17 and IL-17F by naive wild-type 
or RORγt-deficient CD4+ T cells stimulated with different cytokines (above plots). IL-21 
(50 ng/ml) was used and cells were assessed after 96 h of stimulation. Percent cells 
indicated by numbers in quadrants a,b. (Zhou et al., 2007) 
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Figure 7 C: Immunoblot of RORγt 
expression in response to IL-21 
stimulation of naive CD4+ T cells 
stimulated for 48 h as described in b; 
nuclear extracts were analyzed. HMG1was 
loading control. *, nonspecific band 
corresponding to the heavy chain of the 
hamster antibody detected by the 
secondary antibody. (Zhou et al., 2007). 
 
 
Role of STAT 3 and RORγt in IL-17 production 
IL-12 and IL-23 share a subunit on their receptors, IL-12Rβ1, but each also uses a 
distinct subunit that, when stimulated by a ligand, activates STAT proteins. IL-23 
activates STAT3 proteins through tyrosine phosphorylation (Hwang, 2010). STAT3 is 
important in IL-17 production because it has binding sites for both promoters of IL-17A 
and IL-17F genes (Chen et al., 2006). This was proven through chromatin 
immunoprecipitation and q-PCR, which showed that STAT3 has binding sites for IL-17A 
and IL-17F (Figure 8 e) (Chen et al., 2006). 
These results show that STAT3 is important in the production of IL-17, but (Zhou 
et al., 2007) wanted to test if STAT3 is necessary for the differentiation of T cells, not 
just the production of the IL-17 cytokine. The active form of STAT3 (STAT3C) was 
introduced into naïve CD4+T cells. These T cells, when stimulated by STAT3C in the 
presence of IL-6 and TGFβ showed increased numbers of IL-17 producing T cells (Zhou 
et al., 2007). However, STAT3C alone did not induce differentiation of Th17 cells 
(Figure 8 b). STAT3 helps produce IL-17 but is not involved in the differentiation of the 
cell from a naïve T cell to an active, differentiated Th17 cell (Zhou et al., 2007). 
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Previous results indicated that RORγt transcription factor is necessary for 
induction of Th17 cell differentiation. An experiment by Zhou et al. investigated the role 
of STAT3 on IL-17 production and T cell differentiation when coupled with RORγt 
(Zhou et al., 2007). Naïve T cells stimulated with RORγt alone expressed IL-17, as 
expected. Naïve T cells stimulated with RORγt and activated STAT3C showed markedly 
increased amounts of IL-17 production and Th17 cells (Figure 8 c). These results indicate 
that STAT3 helps RORγt in the increased production of IL-17. 
 
Figure 8 e. Levels of binding of STAT3 to IL-A and IL-F promoter regions. T cells were 
activated with plate-bound anti-CD3 and anti-CD28 for 2 days, expanded in IL-2-and stimulated 
with IL-2, IL-4, IL-12, or IL-23 for 15 min to 6 hours. Stat3 binding to the IL-17A and IL-17F 
promoter regions was assessed by chromatin immunoprecipitation. The DNA eluted from Stat3 
precipitated samples was quantified by q-PCR. Values were normalized to input value and are 
expressed as fold enrichment relative to normal rabbit serum (NRS) for each experiment. (Chen 
et al., 2006) 
 
Figure 8 a,b,c STAT3 and RORgammat to induce 
IL-17 expression. Flow cytometry of IL-17 
production in a) WT, b) RORdeficient mice, 
transduced with STAT3C and treated with 
cytokines. c) flow cytometry of IL-17 expression 
encoding MIG and/or RORgammat or STAT3C or 
STAT3F. Baseline IL-17 staining in cells expressing 
RORgammat were increased (Zhou et al., 2007). 
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Discussion:  
 In this study, the factors responsible for inducing Th17 cell differentiation and 
proliferation were investigated. Differentiation of naïve T cells into Th17 cells involves a 
milieu of cytokines and transcription factors, including IL-6, IL-21, IL-23, Foxp3, 
Smad2, 3, and 4, TGFβ, and most importantly RORγt,. Varying the amounts of these 
particular cytokines and transcription factors determines the fate of the naïve T cells, 
particularly the reciprocal differentiation of Treg cells and Th17 cells (Yang, Nurieva, et 
al., 2008). “Although active TGF-b signaling regulates both iTreg and Th17 cell 
differentiation, different downstream molecules may be utilized to regulate the 
development of these two T cell lineages,” (Lee et al., 2009). Although it is necessary to 
have IL-6 present in the differentiation of Th17 cells, it is equally as important to have 
TGFβ as well, because cells with inhibited TGFβ receptors will not differentiate and 
produce IL-17 (Figure 4A).  
 TGFβ is produced in its latent form and needs to be activated by either proteolytic 
degradation, or undergo conformational changes in the latency-associated protein. The 
latency-associated protein is a heterotetrameric protein, which confines the binding of the 
TGFβ homodimer to its receptor for activation(Wrana et al., 1992). Once TGFβ is 
activated, it interacts with the naïve T cell along with IL-6 to activate STAT3, which is 
needed for the induction and to increase effectiveness of RORγt transcription factor 
(Figure 8e) (Zhou et al., 2007). TGF beta increases IL-17 production after exposure to 
IL-6 and halts Th17 differentiation when exposed to IL-23, but only if there is no IL-23R 
receptor subunit. If the cell contains IL-23R, the cells can use IL-23 as a replacement for 
IL-6 in IL-17 production (Figure 7c)(Zhou et al., 2007). 
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 It was also determined that the phosphorylation of Smad proteins does not affect 
the levels of IL-17 produced in Th17 cells. Lee et al. examined the effect of Smad4 
proteins on Th17 development because these proteins function much like STAT3. They 
too translocate into the nucleus where they bind to DNA as a transcription factor. 
However, it was determined that only levels of Foxp3 expression were decreased in 
Smad4 deficient T cells, and that levels of IL-17 production were similar in the mutated 
and wild type cells (Figure 5 E,F) (Lee et al., 2009; Wrana et al., 1992; Yang, Nurieva, et 
al., 2008). 
IL-6 and TGFβ are the key cytokines necessary for Th17 cell differentiation. IL-6 
is the first cytokine in the process of differentiation, which helps induce IL-21 through 
activation of the TCR-CD28 pathway(Yang, Nurieva, et al., 2008). IL-21 can later take 
the place of IL-6 in an autoamplification positive feedback loop (Zhou et al., 2007). IL-
21 helps induce IL-23, which is produced by antigen presenting cells and interacts with 
TGFβ to induce IL-17 production in these differentiated T cells through induction of 
RORγt. IL-6 cannot induce RORγt by itself—it needs TGFβ in order to induce RORγt 
expression as well as to produce IL-23, which is the terminal differentiator for Th17 cells 
(Zhou et al., 2007).  
Although IL-6, IL-21, and IL-23 are all necessary for Th17 cell differentiation, 
they are insufficient to trigger Th17 cell differentiation without RORγt (Zhou et al., 
2007). This is why RORγt is the limiting step in the differentiation of Th17 cells. There 
are many cytokines and chemokines that must interact to induce and aid the RORγt 
transcription factor, but without it, the differentiation will not occur. Thus, if RORγt is 
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inhibited by an exogenous ligand, such as a medication, the Th17 cells cannot 
proliferate(Yang, Nurieva, et al., 2008).  
As seen in both Multiple sclerosis and EAE afflicted mice, Th17 cells are found 
within lesions in the white matter of CNS tissues. These CD4+ T cells attack self-
antigens presented on myelin cells and secrete inflammatory cytokines IL-17, IL-22, IL-
21, and IL-23 that attract neutrophils to the brain (El-behi et al., 2010). Neutrophils, 
along with the inflammatory response, damage the brain and spinal cord, which causes 
the neurological pathophysiology seen in MS and EAE(8,16).  
This study investigated the mechanism of Th17 cell differentiation, because 
control of the differentiation process would decrease the number of Th17 cells and 
therefore decrease the inflammatory damage caused in these diseases. Through thorough 
study of the mechanism leading to the terminal differentiation of naïve T cells into Th17 
cells, it was determined that the RORγt transcription factor was the limiting step (Ivanov 
et al., 2006; Yang, Nurieva, et al., 2008; Zhou et al., 2007). Various cytokines are 
necessary for the induction of the RORγt transcription factor, but this research showed 
that mice with EAE that had T cells deficient in RORγt orphan nuclear receptors have 
limited to no Th17 cell differentiation and thus do not get EAE easily(Ivanov et al., 2006; 
Zhou et al., 2007). Because RORγt has a ligand-binding site, it has good chances of being 





Figure 9. Mechanism of Th17 
cell activation and attack of 
myelin. Th17 cells interact with 
antigen presenting cells and 
release cytokines. The cytokines 
and chemokines initiate 
inflammation and attract other 
immune cells. The infiltration of 
the brain by these immune cells 
mediates the destruction of the 
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Chapter 3—Case Study: Multiple Sclerosis 
Overview 
This case is about a 34 year old, Caucasian woman who was admitted to the 
hospital due to multiple worsening episodes of vision loss, muscle fatigue and weakness, 
and vertigo. The purpose of this study is to investigate the causes of the symptoms and 
differentiate it from other neurological disorders such as Acute Disseminated 
Encephalomyelitis (ADEM), Systemic Lupus Erythematosus, and TIA/Stroke. 	  
Bree Jenkins 
Chief Complaint 
“I woke up and felt dizzy and weak, and then my vision went blurry. Last time 
this happened I had difficulty seeing clearly out of my left eye and my right leg felt weak, 
this time my left eye feels blurry but my right leg feels really weak with some pins and 
needles sensation.”	  
History of Present Illness 
 Bree reported that her symptoms began yesterday around 11am. She said she had 
just left a stressful meeting and felt dizzy when she was at work, but she thought she was 
dehydrated because she had run earlier that morning for exercise. She drank water and ate 
a sandwich to try and relieve her symptoms. Her dizziness persisted, so she went to bed 
early (about 9:30 pm) feeling extremely fatigued. She woke up this morning feeling weak 
in her right leg and experienced vertigo upon standing. Her vision blurred while making 
breakfast at approximately 7:45 am. Her vision returned to normal after about 95 
minutes, but she reported that she still felt as if her “muscles were jelly” and that she 
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lacked strength in her muscles, primarily her right leg. At the time of examination, she 
had been experiencing these symptoms for 25 hours. Bree reports feelings of dizziness 
about every two months or so for the past year and a half, and one incidence of blurred 
left eye vision three months ago, but nothing this severe(“Multiple sclerosis Clinical 
Presentation,” n.d.). She has not been hospitalized for these symptoms previously. She 
normally has 20/20 vision and does not wear any type of corrective lenses. 	  
Social History and Family History 
 Bree grew up in a house with her mother, father, and sister in Colorado. She is the 
older of the two siblings. Her family emigrated from Northern Europe in the 1920’s. Her 
grandparents and parents grew up in Colorado, her birthplace, and she lived there with 
her family for the first 27 years of her life (“Rocky Mountain MS Center,” 2013). She 
then moved to Nevada where she has lived since finishing graduate school. 	  
Her mother and father are still living. Her mother was diagnosed with relapsing-
remitting multiple sclerosis at 47, but aside from that she is healthy and trying to manage 
her symptoms with Tysabri (natalizumab)(“Treating MS - MS Gateway - The Multiple 
sclerosis Gateway,” n.d.). Her paternal side of the family has history of heart disease and 
her father has high cholesterol and is managing it with diet and statins. Her grandfather 
on the paternal side passed from cardiac arrest at 68 years old. Her grandmother passed 
away at age 72 from old age. She reported that her maternal side of the family did not 
have any history of heart disease, cancer, or diabetes, though her grandmother suffered 
GI complications and incontinence towards the end of her life. 	  
Bree has suffered from migraines in the past two years and has taken Excedrin to 
relieve those symptoms. She reports her migraines lasting upwards of four hours. She has 
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not been hospitalized for any major illnesses. Her only surgery was wisdom teeth 
removal at 17 years old, and she did not have any adverse side effects from the 
medication; she decided not to use anesthesia for that procedure. To her knowledge, her 
only medicinal allergy is to penicillin and her only food allergy is shellfish. 	  
Bree is an avid runner but reports that her average mile pace has been slowing 
over the past year and a half because her legs tire more easily, especially her right leg. 
She said she figured this was due to age, not fitness level. She has been physically active 
since high school and has maintained healthy diet and exercise habits. She reports doing 
at least 30 minutes of physical exercise 4-6 times a week.	  
Physical exam 
Bree’s vital signs as recorded by the nurse prior to the physical exam:	  
Height: 5’5”   Weight: 132 lbs    BP: 118/76   Temp: 98.7 F    HR: 69 bpm	  
General: Thin but appears physically fit. Noticeably anxious and worried. 	  
Skin: Skin appears normal. Some freckling and wrinkling but otherwise soft and smooth. 
No rashes. Good color and tone.	  
HEENT:  
Head: Head is symmetrical without any signs of trauma. No frontal, ethmoid, or 
maxillary sinus tenderness. No temporal artery tenderness. No TMJ tenderness.	  
Eyes: Eyes are PERRLA but patient complains of light sensitivity during exam, scleras 
appear normal color, Disc shows mild hyperemia. Fundi appear normal bilaterally. Color 
vision altered.	  
Ears: Normal light reflex seen on tympanic membranes bilaterally.	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Nose: Appears normal. No septal deviation, no nasal discharge or mucosal edema.	  
Mouth: Patient has good dentition without any oral lesions present.	  
Face: Face is symmetrical. No abnormal facies.	  
Neck: Neck is supple, no masses, thyromegaly. Lymph nodes normal. Trachea midline. 
No bruits were heard during auscultation of carotid arteries.	  
Chest/Lungs: Normal chest expansion during full respiration, normal breath sounds 
auscultated bilaterally. No wheezes, rales (crackles), or rhonchi heard. 	  
Heart: RRR, normal S1 and S2 heard, no murmurs, rub, gallop, or bruit detected upon 
auscultation. 	  
Abdomen: Appears symmetrical, normal bowel sounds heard in each quadrant, no pain 
on palpation, no hepatosplenomegaly.	  
Musculoskeletal: Muscle tone appears normal in all extremities No skeletal deformities, 
no edema or tenderness noted. Spine is aligned and normal.	  
Neurological: 
No facial droop. Speech is clear.  Patient is cooperative and gives appropriate responses. 
Cranial nerves 2-12 intact although jerk nystagmus was observed bilaterally, eye exam 
showed 20/20 in right eye and 20/50 in left eye. No fasciculation observed in extremities, 
muscle strength 5/5 in shoulders, arms, and fingers bilaterally, muscle strength 2/5 
observed with right dorsiflexion and plantarflexion, muscle strength 5/5 in left leg. 
Reflexes in biceps and triceps were 2+ bilaterally. Patellar tendon and Achilles reflex was 
3+ in right leg and 2+ in left leg. Babinski reflex was also observed on the right side. 
Sensation in face, shoulders, arms, and fingers was normal bilaterally. Patient had 
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decreased sensation in right leg and left leg sensation was normal. Patient exhibited an 
ataxic gait when walking heel to toe. Patient began falling to the right during Romberg 
test(Mandegary, 2014).	  	  
Laboratory and Imaging Results	  
Table 1: Bree’s Laboratory Findings:(“CBC: MedlinePlus Medical Encyclopedia,” n.d., 
“Common Laboratory Values,” 2012) 
Test	   Reference Value Result	  
CBC	  
RBC Count 4-6 x 1012 cells/L 4.6 x 1012 cells/L	  
Hemoglobin 120-180g/L 132 g/L	  
Hematocrit 35-50% 38%	  
MCV 80-95 fL 91 fL	  
MCH 27-31pg/cell 29 pg/cell	  
MCHC 320-360 332 g/L	  
White Cell Count 4.5-10 x 109 cells/L 8.7 x 109 cells/L	  
Neutrophil Count (Absolute)  5.4 x 109 cells/L	  
Neutrophil Count (Relative) 54-62% 61.8%	  
Lymphocyte (Absolute)  2.6 x 109 cells/L	  
Lymphocyte (Relative) 25-30% 29.8%	  
Monocyte Count (Absolute)  0.5 x 109 cells/L	  
Monocyte Count (Relative) 0-9% 5.7%	  
Eosinophil Count (Absolute)  0.09 x 109 cells/L	  
Eosinophil Count (Relative) 1-3% 1%	  
Basophil Count (Absolute)  0.06 x 109 cells/L	  
Basophil Count (Relative) 1% 0.7%	  
Platelet Count 150-400 x 109 cells/L 325 x 109 cells/L	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MPV 7.5-11.5 fL 8.2 fL	  
BMP	   	  
Sodium 135-147 mmol/L 140 mmol/L	  
Potassium 3.5-5 mmol/L 4.1 mmol/L	  
Chloride 100-106 mmol/L 102 mmol/L	  
Bicarbonate 24-30mmol/L 26 mmol/L	  
BUN 7-20mg/dL 12mg/dL	  
Creatinine 62-106umol/L 82.4 umol/L	  
Glucose <5.6 mmol/L 5.1 mmol/L	  
Antinuclear Antibody   Normal: negative Negative, titer 1:160	  
Vitamin B12  200-900 pmol/L 354 pmol/L	  
Cholesterol  <5.2 mmol/L 5.08 mmol/L	  
LDL 2.6-3.3 (ideal) 2.98 mmol/L	  














Bree’s standard and low-dose nonenhanced CT scan (without contrast) results:	  
There was no mass effect, hemorrhage or hydrocephalus detected. The basal 
cisterns and foramen magnum are patent. The air cells of the petrous temporal bone are 
non-opacified. No fractures identified. No signs of infarction. 
	  
Figure 10: Images A-F show standard and low-dose nonenhanced CT scan (without 
contrast). 	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Bree’s Multiplanar MRI scan (with/without Gadolinium (Gd) contrast) results:	  
There are multiple lesions in subcortical and periventricular white matter.  Corpus 
callosum and posterior fossa appear normal. 	  Possible lesion along left optic nerve is seen 
on axial images. 	  No diffusion-weighted abnormalities.	  
	  
Figure 11: “(A) T2 weighted image; (B) proton density (PD) weighted image; (C) fluid 
attenuated inversion recovery (FLAIR) image; (D) T1 weighted image following 
administration of gadolinium (Gd).”	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Differential Diagnosis 
Bree’s CBC and BMP results were all normal. CT scans normal (Figure 1). Due 
to a negative ANA panel, no rashes found in the physical exam, normal renal function as 
indicated by her BMP, and lack of other systemic symptoms Systemic Lupus 
Erythematosus is an unlikely cause of her symptomatology (Mandegary, 2014).	  
Her neurological symptoms (left eye blur and right leg weakness) are present in 
different areas of her body and on opposite sides. If she had suffered a hemorrhagic 
stroke, it would have been visible on the CT scans. She could have had an ischemic 
stroke which would have been visible on the CT scan considering her symptoms had 
lasted over 24 hours, but again the CT scans were normal(Mandegary, 2014). This, along 
with her overall good health, non-smoking lifestyle, normal cholesterol levels, and no 
prescription for birth control makes TIA/stroke an unlikely diagnosis. 	  
It is doubtful that ADEM is the cause of her symptoms due to her age and its 
rarity in adults. Her HPI indicated she lacked common symptoms of ADEM (headache, 
vomiting, drowsiness) and she reported not having a recent infection, which would 
trigger ADEM (Dale & Branson, 2005). Leukocyte counts are also elevated in ADEM 
patients; her leukocyte count was normal. The bilateral periventricular plaques found on 
her MRI with Gd. contrast (Figure 2) indicate demyelination of her CNS tissue. 
Periventricular plaques are uncommon in ADEM patients. This, coupled with the defined 
edges and multiplicity of the lesions, is indicative of MS(Rolak & Fleming, 2007). 





Based on the positive MRI showing multiple periventricular lesions within her 
CNS tissue—including damage to the left optic nerve—	  the duration and frequency of her 
symptoms reported in the HPI, and her FH of Multiple sclerosis on her maternal side, it 
was determined that a spinal tap was unnecessary to diagnose Bree with relapsing-
remitting Multiple sclerosis. 
Treatment 
 Bree was admitted to the hospital where she was administered 500mg of IV 
methylprednisolone for three days until her symptoms remitted. She also began a 
physical therapy program while hospitalized to strengthen her right leg (Mandegary, 
2014). She was provided with a cane to aid her walking as desired until her strength 
returned to normal. Bree was referred to a neurologist to continue her care, where 
administration of an interferon β-1a blocker, such as Avonex, could be discussed to try 
and mitigate her symptoms and prevent relapse (“Treating MS - MS Gateway - The 
Multiple sclerosis Gateway,” n.d.). 	  
Prognosis 
 At present, Bree’s MS is incurable. The methylprednisolone should reduce the 
immediate inflammation in her CNS to relieve her initial symptoms. Interferon β -1a 
blockers such as Avonex have been shown to prevent the frequency of relapses, which 
should mitigate some of her symptoms. Due to her FH of MS on her maternal side, it is 
likely that her disease will become primary progressive MS in the future. Despite her 
42 
potential worsening symptoms, she has a normal life expectancy (“MS Prognosis and 
Life Expectancy: What You Need to Know,” n.d.).	  
Plan Implementation 
Bree will be referred to a neurologist and should schedule appointments on a 
regular basis to continue her neurological care and manage her medications. If her MS 
appears to worsen or she returns to the hospital with a relapse, her neurologist may try 
changing her medication to one with immunosuppressive properties, such as natalizumab. 
There are risks with switching to immunosuppressive medications, including increasing 
chance of infection (“Treating MS - MS Gateway - The Multiple sclerosis Gateway,” 
n.d.). She will be established with a physical therapist to continue a strength rehabilitation 
program for her right leg until it has returned to normal strength and function.	  
If her MS progresses, she may need corrective lenses for her vision, to reduce her 
activity level, and might have driving restrictions depending on her right leg function. 
She will need to have alternative transportation (family, significant other etc.) to transport 
her if she is unable to drive.  
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